LONN Stock Overview
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF329.20 |
| 52 Week High | CHF599.40 |
| 52 Week Low | CHF308.60 |
| Beta | 0.66 |
| 1 Month Change | -1.56% |
| 3 Month Change | -31.96% |
| 1 Year Change | -28.01% |
| 3 Year Change | -40.25% |
| 5 Year Change | 9.19% |
| Change since IPO | 258.61% |
Recent News & Updates
Calculating The Intrinsic Value Of Lonza Group AG (VTX:LONN)
Dec 06
Is Lonza Group (VTX:LONN) A Risky Investment?
Oct 31Recent updates
Calculating The Intrinsic Value Of Lonza Group AG (VTX:LONN)
Dec 06Is Lonza Group (VTX:LONN) A Risky Investment?
Oct 31A Look At The Fair Value Of Lonza Group AG (VTX:LONN)
Sep 03Lonza Group AG Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
Jul 26Lonza Group (VTX:LONN) Has A Pretty Healthy Balance Sheet
Jul 22With EPS Growth And More, Lonza Group (VTX:LONN) Makes An Interesting Case
May 20These 4 Measures Indicate That Lonza Group (VTX:LONN) Is Using Debt Reasonably Well
Apr 11If EPS Growth Is Important To You, Lonza Group (VTX:LONN) Presents An Opportunity
Feb 14Lonza Group (VTX:LONN) Seems To Use Debt Quite Sensibly
Dec 26Is Now The Time To Put Lonza Group (VTX:LONN) On Your Watchlist?
Oct 25Lonza Group (VTX:LONN) Seems To Use Debt Quite Sensibly
Sep 16Do Lonza Group's (VTX:LONN) Earnings Warrant Your Attention?
Jul 24Does Lonza Group (VTX:LONN) Have A Healthy Balance Sheet?
Jun 09Does Lonza Group (VTX:LONN) Have A Healthy Balance Sheet?
Dec 04Lonza Group (VTX:LONN) Has A Somewhat Strained Balance Sheet
Aug 20We Think Lonza Group (VTX:LONN) Can Stay On Top Of Its Debt
May 10How Many Lonza Group Ltd (VTX:LONN) Shares Do Institutions Own?
Mar 08The Lonza Group Ltd (VTX:LONN) Analysts Have Been Trimming Their Sales Forecasts
Feb 10Here's Why Lonza Group (VTX:LONN) Has A Meaningful Debt Burden
Feb 05
Shareholders of Lonza Group (VTX:LONN) Must Be Delighted With Their 332% Total Return
Jan 15Is Weakness In Lonza Group Ltd (VTX:LONN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Dec 25Are Institutions Heavily Invested In Lonza Group Ltd's (VTX:LONN) Shares?
Dec 07Here's Why I Think Lonza Group (VTX:LONN) Might Deserve Your Attention Today
Nov 18Shareholder Returns
| LONN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -1.7% | -0.8% | 1.4% |
| 1Y | -28.0% | -22.3% | -1.1% |
Return vs Industry: LONN underperformed the Swiss Life Sciences industry which returned -22.7% over the past year.
Return vs Market: LONN underperformed the Swiss Market which returned -1.3% over the past year.
Price Volatility
| LONN volatility | |
|---|---|
| LONN Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 4.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: LONN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LONN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 17,896 | Albert Baehny | https://www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LONN fundamental statistics | |
|---|---|
| Market Cap | CHF24.45b |
| Earnings (TTM) | CHF1.13b |
| Revenue (TTM) | CHF6.32b |
21.7x
P/E Ratio3.9x
P/S RatioIs LONN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONN income statement (TTM) | |
|---|---|
| Revenue | CHF6.32b |
| Cost of Revenue | CHF3.97b |
| Gross Profit | CHF2.35b |
| Other Expenses | CHF1.22b |
| Earnings | CHF1.13b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.20 |
| Gross Margin | 37.19% |
| Net Profit Margin | 17.87% |
| Debt/Equity Ratio | 28.1% |
How did LONN perform over the long term?
See historical performance and comparison